A Study of AK129 in Patients With Advanced Malignant Tumors
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3
bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in
patients with advanced malignant tumors